|
CA3106429A1
|
|
Method for improving anticancer agent efficacy
|
|
AU2019320483A1
|
|
Compositions for the treatment of graft versus host disease
|
|
US2020318094A1
|
|
Beta-lactamase variants
|
|
EP3420078A1
|
|
Beta-lactamase variants
|
|
US2019048331A1
|
|
Beta-lactamase variants
|
|
EP3359165A1
|
|
Suppression or reduction of the pathogenicity or virulence of a clostridium bacteria
|
|
EP2868632A1
|
|
Method for the inactivation of virginiamycin
|
|
WO2012085241A1
|
|
Compositions and methods for the controlled repopulation of gram-negative bacteria in the colon
|
|
CN102869351A
|
|
Formulations for oral delivery of adsorbents in the gut
|
|
EP2407433A1
|
|
Methods for the inactivation of antibiotics
|
|
KR20120004448A
|
|
Compositions and methods for elimination of gram-negative bacteria
|
|
WO2009037264A2
|
|
Colonic delivery of antimicrobial agents
|
|
EP2081557A1
|
|
Colonic delivery using zn/pectin beads with a eudragit coating.
|
|
EP2386308A1
|
|
Site-specific intestinal delivery of adsorbents, alone of in combination with degrading molecules
|
|
WO2006122835A1
|
|
Colonic delivery of adsorbents
|
|
CN101128187A
|
|
Colonic delivery of active agents
|
|
EP1992336A2
|
|
Dosage form for the administration of active agents in the colon
|
